| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Collaboration revenue | $117K | — | — | $10K | — |
| Total revenue | $117K | — | — | $10K | — |
| Cost of collaboration revenue | $95K | — | — | $800 | — |
| Total cost of revenue | $95K | — | — | $800 | — |
| Gross profit | $22K | — | — | $9K | — |
| Research and development | $1.8M-19.0% | $2.2M+55.2% | $1.4M+135.1% | $609K+2337.1% | $25K |
| General and administrative | $4.8M-3.9% | $5.0M+25.5% | $4.0M+115.3% | $1.9M+466.9% | $327K |
| Total operating expenses | $6.6M-8.6% | $7.2M+33.3% | $5.4M+120.2% | $2.5M+343.9% | $555K |
| Loss from operations | -$6.6M+8.9% | -$7.2M-34.8% | -$5.4M-118.6% | -$2.5M-342.2% | -$555K |
| Interest expense | -$6K+69.0% | -$18K+77.0% | -$79K | — | -$40K |
| Interest income | $102K-60.8% | $261K+42.0% | $184K+39922.4% | $459 | — |
| Total other income (expense), net | $97K-60.2% | $243K+1982.7% | $12K+103.4% | -$347K-1037.5% | -$30K |
| Net loss | -$6.5M+7.1% | -$7.0M-30.6% | -$5.4M-91.1% | -$2.8M-378.4% | -$586K |
| Deemed dividend related to warrant exercise price adjustment | -$45K | — | — | — | — |
| Net loss attributable to common stockholders | -$6.5M+7.7% | -$7.0M-31.4% | -$5.4M | — | — |
| Net loss per common share attributable to common stockholders - basic | -$0.63+25.9% | -$0.85+4.5% | -$0.89-27.1% | -$0.70+95.0% | -$14.00 |
| Net loss per common share attributable to common stockholders - diluted | -$0.63+25.9% | -$0.85+4.5% | -$0.89-27.1% | -$0.70 | — |
| Weighted average number of shares outstanding - basic | 10.3M+25.4% | 8.2M+36.3% | 6.0M+50.9% | 4.0M-2.6% | 4.1M |
| Weighted average number of shares outstanding - diluted | 10.3M+25.4% | 8.2M+36.3% | 6.0M+50.9% | 4.0M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.